venBio Select Advisor LLC acquired a new position in shares of Loxo Oncology Inc (NASDAQ:LOXO) in the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 325,000 shares of the biopharmaceutical company’s stock, valued at approximately $45,523,000. Loxo Oncology accounts for 2.7% of venBio Select Advisor LLC’s holdings, making the stock its 12th largest holding.
Several other large investors also recently bought and sold shares of LOXO. Exane Derivatives purchased a new position in shares of Loxo Oncology during the 4th quarter worth approximately $43,000. Dorsey Wright & Associates boosted its position in shares of Loxo Oncology by 20.0% during the 4th quarter. Dorsey Wright & Associates now owns 312 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 52 shares during the period. Meeder Asset Management Inc. boosted its position in Loxo Oncology by 177.0% in the 4th quarter. Meeder Asset Management Inc. now owns 338 shares of the biopharmaceutical company’s stock valued at $48,000 after buying an additional 216 shares during the period. Cornerstone Advisors Inc. boosted its position in Loxo Oncology by 46.0% in the 4th quarter. Cornerstone Advisors Inc. now owns 387 shares of the biopharmaceutical company’s stock valued at $54,000 after buying an additional 122 shares during the period. Finally, Advisor Group Inc. boosted its position in Loxo Oncology by 78.4% in the 4th quarter. Advisor Group Inc. now owns 505 shares of the biopharmaceutical company’s stock valued at $71,000 after buying an additional 222 shares during the period. 96.49% of the stock is owned by hedge funds and other institutional investors.
Several brokerages have commented on LOXO. Zacks Investment Research raised shares of Loxo Oncology from a “sell” rating to a “hold” rating in a research report on Friday, November 16th. BidaskClub cut shares of Loxo Oncology from a “buy” rating to a “hold” rating in a research report on Wednesday, February 13th. William Blair reissued a “buy” rating on shares of Loxo Oncology in a research report on Tuesday, November 27th. Leerink Swann cut shares of Loxo Oncology from an “outperform” rating to a “market perform” rating in a research report on Monday, January 7th. Finally, JMP Securities reissued a “buy” rating and issued a $215.00 price target on shares of Loxo Oncology in a research report on Thursday, November 29th. Eight investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. Loxo Oncology presently has an average rating of “Buy” and a consensus price target of $198.58.
ILLEGAL ACTIVITY NOTICE: “venBio Select Advisor LLC Invests $45.52 Million in Loxo Oncology Inc (LOXO)” was originally posted by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://dakotafinancialnews.com/2019/03/15/venbio-select-advisor-llc-invests-45-52-million-in-loxo-oncology-inc-loxo.html.
Loxo Oncology Profile
Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.
Featured Story: How is the LIBOR rate calculated?
Want to see what other hedge funds are holding LOXO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Loxo Oncology Inc (NASDAQ:LOXO).
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.